If you're asking whether weight loss shots like tirzepatide are safe over the long run, here is the short answer. The FDA label for Zepbound carries a boxed warning about thyroid C-cell tumors seen in rats, and the label says it is unknown whether the drug causes these in humans. The longest studies ran about three to four years, so the effects of decades of use are not yet known. The common problems are digestive, such as nausea, diarrhea and constipation, and they tend to show up while the dose is rising. The label also lists more serious risks, including gallbladder disease, pancreatitis, kidney injury and low blood sugar.
Affiliate disclosure: Plainly, some links on this page are affiliate links. Buying through them may earn us a commission. You pay no more either way.
Here are the key facts, as of 2026-11-18.
| Fact | What the sources say, as of 2026-11-18 |
|---|---|
| Brand names | Zepbound is approved for weight management and Mounjaro for type 2 diabetes. Both are tirzepatide (WebMD's prescription weight loss guide). |
| Boxed warning | Thyroid C-cell tumors in rats; human relevance unknown (FDA Zepbound prescribing information, revised 08/2026). |
| Longest trial data | About three to four years. Ro describes a three-year extension in 1,032 adults and a heart trial with a median follow-up of about four years (Ro, updated Nov 17, 2026). |
| Suicidal ideation warning | Removed from the label, 02/2026 (FDA Zepbound prescribing information, recent changes). |
| Diabetic retinopathy warning | Added to the label, 08/2026, for people with type 2 diabetes (FDA Zepbound prescribing information). |
| Eye warning (NAION) | Ro says the FDA announced a warning in November 2026 for GLP-1-based drugs (Ro, updated Nov 17, 2026). |
| Recent research | A 2025 meta-analysis of six randomized trials with 6,266 adults (2025 meta-analysis of tirzepatide trials). |
Are weight loss shots like tirzepatide safe for the long term?
Consumer Reports says some of these medicines, used to treat diabetes for over two decades, are generally considered safe. It adds that more research is needed in groups such as older adults (Consumer Reports on weight loss drugs). So the useful question is which risks matter for you.
A 2025 meta-analysis of six randomized trials, with 6,266 adults, found tirzepatide produced more weight loss than placebo or other GLP-1 drugs. Its gastrointestinal side effects were similar across the three doses and to GLP-1 drugs, and higher than placebo. The authors wrote that “the lean mass reduction and tolerability require further investigation.”
What is the boxed warning on tirzepatide?
The boxed warning is about thyroid tumors seen in rats. The FDA label says that in rats, tirzepatide causes “dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures.” It also says it is unknown whether Zepbound causes these tumors, including medullary thyroid carcinoma, in humans.
The label lists the drug as contraindicated for anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. It adds that routine calcitonin monitoring or thyroid ultrasound is “of uncertain value” for early detection.
WebMD describes it the same way: the drug “has been shown in studies to cause thyroid tumors in animals, but it's not yet known if it can cause thyroid cancer in people.”
What are the long-term side effects of tirzepatide?
The table below sets out the main risks, what the label says about each, and how often they showed up in trials. Ro, a telehealth company that sells tirzepatide prescriptions, reports the rates from the label's 72-week weight trials. Its Ro long-term side effects article is seller content, so read it as a summary.
| Risk | What the label says | How common if given |
|---|---|---|
| Thyroid C-cell tumors | Boxed warning. Seen in rats. Contraindicated with personal or family history of MTC or MEN 2. | Unknown in humans, according to the label. |
| Common digestive effects | Most common reactions (5% or more) include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, reflux and hair loss. | Constipation 11-17% vs 5% placebo; reflux 4-5% vs 2%; indigestion 9-10% vs 4%; fatigue 5-7% vs 3%; hair loss up to 5% vs 1% (Ro). |
| Severe digestive reactions | Warning. Not recommended in severe gastroparesis. | Severe in 1.7% at 5 mg, 2.5% at 10 mg and 3.1% at 15 mg, vs 1% on placebo (FDA label). |
| Gallbladder disease | Warning on gallstones, gallbladder inflammation and gallbladder removal. | Gallstones 1.1% vs 1%; inflammation 0.7% vs 0.2%; gallbladder removal 0.2% vs none (FDA label). |
| Acute pancreatitis | Warning, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis. Discontinue if suspected. | 0.2% vs 0.2% on placebo (Ro, from the label's trials). |
| Acute kidney injury | Warning on kidney injury from dehydration. | 0.5% vs 0.2% (Ro, from the label's trials). |
| Low blood sugar | Warning. Higher risk when taken with a sulfonylurea. | 4.2% vs 1.3% in the diabetes trial; 10.3% with a sulfonylurea vs 2.1% without (FDA label). |
| Severe allergic reactions | Warning on hypersensitivity. | Severe in 0.1% vs none (FDA label). |
| Vision loss (NAION) | Ro says the FDA announced a warning in November 2026 for GLP-1-based drugs. | About 6 per 100,000 per year on GLP-1 drugs vs about 4 per 100,000 on placebo or other diabetes drugs, in an FDA analysis of 126 trials (Ro). |
| Diabetic retinopathy complications | Warning added 08/2026. | Applies to people with type 2 diabetes (FDA label). |
Are there new warnings on tirzepatide?
Yes. The FDA label has recent 2026 changes. The suicidal behavior and ideation warning was removed in 02/2026, and a diabetic retinopathy warning for type 2 diabetes was added in 08/2026.
Ro says the FDA announced a warning in November 2026 on non-arteritic anterior ischemic optic neuropathy (NAION) for GLP-1-based drugs. Consumer Reports describes the class risk as rare, a loss of blood flow to the optic nerve that “can cause permanent loss of vision.”
How long have people been studied?
Ro describes a three-year extension in 1,032 adults with obesity and prediabetes. It found no new safety concerns, with digestive effects most common and early. Ro also describes SURPASS-CVOT, a heart trial of more than 13,000 adults with type 2 diabetes and heart disease, followed for a median of about four years. Digestive problems were more common than with dulaglutide in that trial.
A 2025 review of semaglutide and tirzepatide safety looked at post-marketing concerns. It lists nausea, vomiting, pancreatitis and diarrhea, and says “bone remodeling, kidney and thyroid disorders were detected.” That review covers both drugs, not tirzepatide alone.
What are the common mix-ups?
Rat tumors vs human data. The thyroid tumor finding comes from rats. The label says it is unknown whether the drug causes these tumors in humans. A rat finding is not a human result.
Zepbound vs Mounjaro. These are the same drug, tirzepatide. Zepbound is approved for weight management, and Mounjaro is approved for type 2 diabetes (WebMD).
Reports vs proof. Ro cites 37,827 FDA adverse event reports in the first two years, with 93.9% from consumers. Ro notes that such reports “can't always prove” the drug caused the problem.
Compounded versions. WebMD cites an FDA warning that compounded versions may be a different formula from the branded product and “may not be effective or safe.” That warning is about compounded semaglutide, not tirzepatide. Ask your pharmacist exactly what you are being given.
When do side effects start, and how long do they last?
Ro says the common effects, including nausea, diarrhea, vomiting and constipation, usually appear in the first few months while the dose rises. WebMD says they “usually go away after you get to the dose you've been prescribed and your body adjusts, but sometimes they can be serious.”
Consumer Reports says digestive side effects may be more frequent in older adults. It quotes a geriatric obesity specialist who says eating frequent small meals may minimize them.
Who needs extra care before starting?
- Personal or family history of MTC or MEN 2. The label lists this as a contraindication.
- Pregnancy. The label says tirzepatide may cause fetal harm and should be discontinued when pregnancy is recognized.
- Birth control pills. The label says oral contraceptive users should switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.
- Severe gastroparesis. The label says it is not recommended.
- Insulin or other diabetes medicines. WebMD says you shouldn't take GLP-1s at the same time as insulin or certain other diabetes medications, or your blood sugar could drop dangerously low. Ask your doctor or pharmacist how this applies to you.
- Anesthesia or deep sedation. The label warns about pulmonary aspiration in these settings.
- Gallbladder, pancreas or kidney history. The label lists gallbladder disease, pancreatitis and kidney injury as warnings, so raise these histories before you start.
- Older adults. Consumer Reports points to more research needed in this group. A 2026 study it cites found adults with type 2 diabetes who started a GLP-1 had an 11% higher fracture risk than those on other diabetes medicines.
The label also says never to share a KwikPen.
What happens if you stop, and can you keep the weight off?
Ro reports the SURMOUNT-4 withdrawal trial. In it, 670 adults lost 20.9% over 36 weeks. Those switched to placebo regained 14% over 52 weeks, while those who stayed on the drug lost another 5.5%. Of the stopped group, 16.6% kept at least 80% of their loss, compared with 89.5% of the continued group.
WebMD says that “you may have to stay on Zepbound for life for weight management” and that “quitting it can lead to regaining much of the weight you lost.” The label's indication is to reduce excess body weight and maintain it long term, alongside a reduced-calorie diet and more activity. Changes to dosing or stopping should go through your prescriber. For the wider picture on maintenance, see our long-term weight management guide.
Can diet help with side effects?
Consumer Reports lists rules for limiting muscle loss on GLP-1 drugs: at least 30 grams of protein per meal, plus 15 to 20 minutes of resistance activity two or more times a week alongside aerobic exercise such as brisk walking. It also suggests frequent small meals for digestive side effects.
What should you ask your doctor or pharmacist?
- Do I have a personal or family history of medullary thyroid carcinoma or MEN 2?
- Do I take insulin, a sulfonylurea or birth control pills?
- Do I have a history of gallbladder, pancreas or kidney problems?
- What is the plan if nausea or constipation lasts past the first few months?
- What is my plan for long-term use and for stopping?
If you're weighing tirzepatide against other routes, our semaglutide vs tirzepatide results page sets out the trial numbers, and our top tirzepatide alternatives guide covers the other options.
By SterlingMedicalCenter.org Editorial Team
Read next